Media Thread, page-207

Hi Oxxa,

Thank you for all your efforts here, I think the videos are a great way to understand how Cancer Immunotherapy works, it’s quite complex.

We already knew about this Keytruda/Yervoy trial fail, SAEs including fatal events & in comparison to our Gastric Ca trial advised to halt early on positive data, this one was halted early due to futility & safety concerns including fatal events.

What’s the connection? - Imugene’s PD1-Vaxx is being trialled in the same indication Non Small Cell Lung Ca, including in the USA and Australia (recruiting) following recent FDA approval for IND.

https://immuno-oncologynews.com/2020/11/25/merck-halts-phase-3-keynote-598-trial-yervoy-keytruda-combo-lung-cancer/?cn-reloaded=1

My question is how long will it be before IMU Immunotherapies are being trialled with the likes of Keytruda or Yervoy & not chemo alone?

From what we have seen so far, this totally makes sense. While our Immunotherapies B-Vaxx & PD1-Vaxx are showing very promising results in pre-clinical, PD1-Vaxx currently in Ph1 clinical trials, I wouldn’t be surprised if IMU get a tap on the shoulder for a collaboration.

It’s not all about Roth valuation, they may need to update that 20c SP target in the near future...again.

No hype train, it is what it is...a Unicorn, Her-Vaxx interim data has just shown us a peek of the horn.

GLTAH